Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) Receives Average Rating of “Hold” from Analysts
Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) has been given an average recommendation of “Hold” by the seven brokerages that are presently covering the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $26.29.
A number of equities research analysts have recently issued reports on ENTA shares. Zacks Investment Research lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, July 28th. JPMorgan Chase & Co. set a $26.00 price target on Enanta Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 9th.
Hedge funds and other institutional investors have recently modified their holdings of the company. Fiera Capital Corp acquired a new position in shares of Enanta Pharmaceuticals during the second quarter valued at $12,480,000. Spark Investment Management LLC raised its position in shares of Enanta Pharmaceuticals by 302.6% in the second quarter. Spark Investment Management LLC now owns 293,100 shares of the company’s stock valued at $6,462,000 after buying an additional 220,300 shares during the last quarter. Senzar Asset Management LLC raised its position in shares of Enanta Pharmaceuticals by 42.2% in the second quarter. Senzar Asset Management LLC now owns 482,000 shares of the company’s stock valued at $10,628,000 after buying an additional 143,149 shares during the last quarter. Emerald Acquisition Ltd. acquired a new position in shares of Enanta Pharmaceuticals during the second quarter valued at $2,420,000. Finally, Mcclain Value Management LLC raised its position in shares of Enanta Pharmaceuticals by 75.4% in the second quarter. Mcclain Value Management LLC now owns 186,850 shares of the company’s stock valued at $4,120,000 after buying an additional 80,342 shares during the last quarter. Institutional investors own 70.82% of the company’s stock.
Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) traded down 0.38% during midday trading on Wednesday, reaching $26.37. The company’s stock had a trading volume of 61,220 shares. The stock’s 50-day moving average is $24.17 and its 200-day moving average is $24.90. The company has a market capitalization of $501.95 million, a P/E ratio of 17.44 and a beta of 0.52. Enanta Pharmaceuticals has a one year low of $16.75 and a one year high of $41.77.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, August 8th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03. Enanta Pharmaceuticals had a return on equity of 11.31% and a net margin of 32.59%. The business earned $14 million during the quarter, compared to analysts’ expectations of $13.07 million. During the same quarter in the prior year, the firm earned $0.13 earnings per share. The business’s revenue was up 20.7% compared to the same quarter last year. On average, equities analysts expect that Enanta Pharmaceuticals will post $1.02 earnings per share for the current fiscal year.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).
Receive News & Stock Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.